Sun said to be discussing $2.3B deal for Intas: DealStreetAsia

Sun Pharmaceutical is reported to be in negotiations to buy Indian rival Intas Pharmaceuticals for as much as $2.3 billion, talks that Intas says are not happening. In an exclusive based on unnamed sources, DealStreetAsia says the two companies are discussing a cash and stock deal that would give Sun entry into biosimilars. Intas is hoping to be the first Indian drugmaker to sell biosimilars in the U.S. with its version of Amgen's ($AMGN) Neulasta. More from FiercePharmaAsia

Suggested Articles

Gilead expects to sell 1 million to 1.5 million treatment courses of remdesivir in 2020. That means about $3.5 billion in sales, one analsyt figures.

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Warp Speed's largest outlay to date, the funding will cover development and manufacturing scale-up of a vaccine that uses proven Sanofi technology.